ClinicalTrials.gg
Active, not recruitingNCT07062848TRACE NetworkUpdated Jul 29, 2026

An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

An observational study in Transthyretin (TTR) Amyloid Cardiomyopathy, sponsored by Yale University. Active, not recruiting at 12 sites in United States. Open to participants aged 50 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Yale University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,500,000
Ages
50 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Amyloid Neuropathies, Familial with a site in United States — 23 open to participants now, 26 under way, 4 of them phase 3. Amyloid Neuropathies, Familial · United States.

Planned enrollment
2nd of 20
1,500,000 · median 125
Started
2025
with 6 others
Observational
20 of 58
12 open now
Primary completion
2027-01
later than 6 of 25 live
Registered
49th of 58
by date

Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, this one is the 2nd largest by planned enrollment of the 20 observational ones that give a count, is one of 7 that started in 2025, is one of 20 observational ones, reaches primary completion later than 6 of the 25 other live ones, and was the 49th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

23 of the 58 studies in Amyloid Neuropathies, Familial with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 50 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Amyloid Neuropathies, Familial with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, observational study with the overall objective to examine the scale of under-diagnosis for transthyretin amyloid cardiomyopathy (ATTR-CM) across a broad range of diverse health systems in the US using a fully federated deployment of an artificial intelligence (AI) toolkit of algorithms that detect ATTR-CM on electrocardiography (ECG), point-of-care ultrasound (POCUS), and transthoracic echocardiography (TTE).

03

Conditions studied

  • Transthyretin (TTR) Amyloid Cardiomyopathy

Keywords

  • artificial intelligence
  • AI-ECG
  • AI-Echo
  • cardiac amyloidosis
  • transthyretin amyloid cardiomyopathy
04

Who can participate

Ages eligible
50 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include US adults ages 50-95 with at least one retrievable ECG and/or 2D echo file from HER.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Broad inclusion and exclusion criteria across all 3 objectives:

Inclusion criteria

Inclusion Criteria:

  • Age 50-95
  • At least one retrievable and/or 2D echo file (DICOM or equivalent video file) from EHR.

Exclusion criteria

Exclusion Criteria:

  • Unavailable key demographics (age, gender, race, ethnicity)
  • Individuals who have opted out of research studies

Objective-specific inclusion and exclusion criteria:

Primary Objective:

Additional exclusion criteria:

  • For subgroup analyses: when evaluating the prevalence of probable ATTR-CM status across demographic groups, we will exclude those with missing baseline demographic information (age, sex, race, geographic region).

Secondary Objective 1:

Additional inclusion criteria:

  • 'Cases': ATTR-CM diagnosis defined by ICD-10 codes (Table 1) OR abnormal bone scintigraphy testing consistent with ATTR-CM OR treatment with an approved transthyretin stabilizer or other ATTR-CM-specific therapy
  • 'Controls': any individuals not meeting the case definition. In these participants, we will consider all eligible , POCUS, or TTE studies performed up to 12 months before diagnosis (first date of ICD code appearance, abnormal bone scintigraphy or treatment onset, whichever happened first) and any time after. 'Controls' will be drawn from ECGs, POCUS, or TTE studies performed in individuals not meeting the 'case' criteria above, including individuals who have never undergone dedicating testing or those who underwent e.g., bone scintigraphy, but with negative (or equivocal) findings.

Secondary Objective 2:

Additional inclusion criteria:

  • Having at least two years of follow-up time between the index test (ECG, POCUS, or TTE) and the date of analysis.
  • Having at least one healthcare encounter every two years across care settings from their first entry into the cohort through death or end of the follow-up period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,500,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testAI Toolkit for ATTR-CM Diagnosis

    An artificial intelligence (AI) toolkit of algorithms that detect ATTR-CM on electrocardiography (ECG), point-of-care ultrasound (POCUS), and transthoracic echocardiography (TTE)

06

What researchers measure

Primary outcomes

  1. To describe the prevalence of probable AI-defined ATTR-CM in defined cohorts of individuals who have undergone standard cardiovascular investigations across a diverse network of US-based health care delivery systems

    Time frame: At enrollment

Secondary outcomes

  1. Validate the diagnostic performance of AI-enabled ECG, POCUS, and TTE algorithms for ATTR-CM

    Time frame: At enrollment

  2. To examine the association between the AI-defined probability of ATTR-CM and the incidence of adverse cardiovascular events

    Time frame: At enrollment

07

Study locations

12 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 14, 2025
StartActual
Jan 24, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07062848
Lead sponsor
Yale University
Collaborators
Bridgebio Pharma, Inc
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jan 24, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Rohan Khera, MD, MS
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion